Get started
Author

Neil Peterman

DNA Translocation through Graphene Nanopores
2010 · Christopher A. Merchant, Ken Healy, et al. · Nano Letters · 904
Discrimination of Methylcytosine from Hydroxymethylcytosine in DNA Molecules
2010 · Meni Wanunu, Devora Cohen-Karni, et al. · Journal of the American Chemical Society · 170
Sort-seq under the hood: implications of design choices on large-scale characterization of sequence-function relations
2016 · Neil Peterman, Erel Levine · BMC Genomics · 100
PDF
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
2022 · Diana Merino Vega, Katherine K. Nishimura, et al. · JCO Precision Oncology · 80
PDF
Fabrication and characterization of nanopores with insulated transverse nanoelectrodes for DNA sensing in salt solution
2012 · Ken Healy, Vishva Ray, et al. · Electrophoresis · 51
Large-scale mapping of sequence-function relations in small regulatory RNAs reveals plasticity and modularity
2014 · Neil Peterman, Anat Lavi-Itzkovitz, et al. · Nucleic Acids Research · 37
PDF
Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors
2020 · Andrew A. Davis, Wade T. Iams, et al. · Molecular Cancer Therapeutics · 33
PDF
Dynamics of translation can determine the spatial organization of membrane-bound proteins and their mRNA
2017 · Elgin Korkmazhan, Hamid Teimouri, et al. · Proceedings of the National Academy of Sciences · 18
PDF
Quantitative effect of target translation on small RNA efficacy reveals a novel mode of interaction
2014 · Anat Lavi-Itzkovitz, Neil Peterman, et al. · Nucleic Acids Research · 13
PDF
Comparison of enzymatic-and bisulfite conversion to map the plasma cell-free methylome in cancer
2019 · N. Lambert, A. Robertson, et al. · Annals of Oncology · 4
Abstract 3362: Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay
2023 · Christopher Sweeney, Chang Xu, et al. · Cancer Research · 3
Abstract 3675: An integrated approach for simultaneous detection of genomic and epigenetic alterations in blood-based ctDNA analysis
2025 · Qin Tang, Becky Wong, et al. · Cancer Research · 1
Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumours
2019 · A.A. Davis, W. Iams, et al. · Annals of Oncology · 1
PDF
P1.01-49 Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC
2019 · A. Davis, W. Iams, et al. · Journal of Thoracic Oncology · 1
PDF
Abstract 5896: Tissue naive comprehensive methylation profiling enhances the identification of ctDNA in lung cancer
2025 · Yu Sun, Nafisa Bulsara, et al. · Cancer Research
Abstract 4568: Biochemical mitigation of technical artifacts improves performance of a ctDNA methyl sequencing assay
2025 · James Yu, Peter George, et al. · Cancer Research
Abstract P5-01-13: Longitudinal changes in whole-genome (WG) cell-free DNA (cfDNA) and methylation as a blood-based biomarker to identify early disease progression in advanced breast cancer
2020 · Andrew A Davis, David Chan, et al. · Cancer Research
Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumours
2019 · A.A. Davis, W. Iams, et al. · Annals of Oncology
EP1.01-94 The Role of Neoadjuvant Chemo-Immunotherapy in Unresectable Non-Small Cell Lung Cancer
2019 · M. Oh, A. Davis, et al. · Journal of Thoracic Oncology
Abstract 2279: Serial changes in tumor-derived whole-genome cfDNA fraction to identify early disease progression prior to imaging
2019 · Andrew A. Davis, Wade T. Iams, et al. · Cancer Research
Abstract 2279: Serial changes in tumor-derived whole-genome cfDNA fraction to identify early disease progression prior to imaging
2019 · Andrew A. Davis, Wade T. Iams, et al. · Clinical Research (Excluding Clinical Trials)
Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.
2019 · Andrew A. Davis, Wade Thomas Iams, et al. · Journal of Clinical Oncology
A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.
2019 · Andrew A. Davis, Wade Thomas Iams, et al. · Journal of Clinical Oncology
Sequence-Function Models of Regulatory RNA in E. Coli
2017 · Neil Peterman · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Additional file 1 of Sort-seq under the hood: implications of design choices on large-scale characterization of sequence-function relations
2016 · Peterman, Neil, Levine, Erel · Figshare
Works count: 27
Citation count: 1,416
H-index: 9
I10-index: 9
Year
Topic
Type